Oligonucleotide analogues and methods utilizing the same

Details Oligonucleotide analogues and methods utilizing the same Oligonucleotide analogues and methods utilizing the same

2007-07-27

2010-10-19

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S04400A, C514S045000, C514S049000, C536S022100, C536S023100, C536S025600, C536S026200, C536S027810, C536S027210, C536S027600, C536S028100

Reexamination Certificate

active

07816333

ABSTRACT:
A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a pharmacologically acceptable salt thereof in the body of said mammal, which method comprises administering to said mammal in need of such prevention or treatment a pharmaceutically effective amount of an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of said nucleoside units is a structure of the formula (2):wherein A is methylene; and B is an unsubstituted purin-9-yl, an unsubstituted 2-oxo-pyrimidin-1-yl or a substituted purin-9-yl; or a pharmacologically acceptable salt thereof.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawi et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5457189 (1995-10-01), Crooke et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5523389 (1996-06-01), Ecker et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5591600 (1997-01-01), Ecker
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5607923 (1997-03-01), Cook et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5658891 (1997-08-01), Draper et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5681747 (1997-10-01), Boggs et al.
patent: 5681944 (1997-10-01), Crooke et al.
patent: 5691461 (1997-11-01), Ecker et al.
patent: 5877309 (1999-03-01), McKay et al.
patent: 5955443 (1999-09-01), Bennett et al.
patent: 5985558 (1999-11-01), Dean et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6127533 (2000-10-01), Cook et al.
patent: 6268490 (2001-07-01), Imanishi et al.
patent: 6670461 (2003-12-01), Wengel et al.
patent: 6794499 (2004-09-01), Wengel et al.
patent: 7034133 (2006-04-01), Wengel et al.
patent: 7217805 (2007-05-01), Imanishi et al.
patent: 2002/0068708 (2002-06-01), Wengel et al.
patent: 2003/0082807 (2003-05-01), Wengel
patent: 2003/0087230 (2003-05-01), Wengel
patent: 2003/0134808 (2003-07-01), Wengel et al.
patent: 2003/0144231 (2003-07-01), Wengel et al.
patent: 2004/0143114 (2004-07-01), Imanishi et al.
patent: 2005/0287566 (2005-12-01), Wengel et al.
patent: 2007/0117773 (2007-05-01), Koizumi et al.
patent: 1 013 661 (2000-06-01), None
patent: WO 94/08003 (1994-04-01), None
patent: WO 96/31557 (1996-10-01), None
patent: WO 98/39352 (1998-09-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 01/18015 (2001-03-01), None
Griffiths et al, “Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Precedes Dermal T Lymphomatic Infiltration . . . ”,American Journal of Path., Dec. 1989, vol. 135, No. 6, pp. 1045-1053.
Thuong et al, “Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides”,Angew. Chem. Int. Ed. Engl., 1993, 32, pp. 666-690.
Manoharan et al, “Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides”,Ann. N.Y. Acad. of Sciences, 1992, 660, pp. 306-309.
Stetler-Stevenson et al, “Tumor Cell Interactions With the Extracellular Matrix During Invasion and Metastasis”,Annu. Rev. Cell Biol., 1993, 9, pp. 541-573.
Cook, “Medicinal chemistry of antisense oligonucleotides—future opportunities”,Anti-Canceer Drug Design, 1991, 6, pp. 585-607.
Sanghvi, “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides”,Antisense Research and Applications, 1993, Chapter 15, pp. 273-288.
Shiohara et al, “Fixed Drug Eruption”,Arch Dermatol., Oct. 1989, vol. 125, pp. 1371-1376.
Mishra et al, “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery”,Biochim. Biophys. Acta, 1995, 1264, pp. 229-237.
Svinarchuk et al, Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups,Biochimie, 1993, 75, pp. 49-54.
Manoharan et al, “Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications”,Bioorg. Med. Chem. Lett., 1993, vol. 3, No. 12, pp. 2765-2770.
Manoharan et al, “Cholic Acid—Oligonucleotide Conjugates for Antisense Applications”,Bioorg. Med. Chem. Lett., 1994, vol. 4, No. 8, pp. 1053-1060.
Lisby et al, “Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation”,Br. J. of Dermatol., 1989, 120, 479-484.
Maher III, “Prospects for the Therapeutic Use of Antigene Oligonucleotides”, Cancer Investigation,Cancer Investigation, 1996, 14(1), pp. 66-82.
Birkedal-Hansen, “Proteolytic remodeling of extracellular matrix”,Current Op. Biol., 1995, 7, pp. 728-735.
LeRoith et al, “Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor”,Endocr. Rev., 1995, vol. 16, No. 2, pp. 143-163.
Kabanov et al, “A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent . . . ”,FEBS Lett., Jan. 1990, vol. 259, No. 2, pp. 327-330.
Martin, “A New Access to 2′-O-Alkylated Ribonucleosides and Properties of 2′-O-Alkylated Oligoribonucleotides”,Helv. Chim. Acta, 1995, vol. 78, pp. 486-504.
DeLisser et al, “Molecular and functional aspects of PECAM-1/CD31”Immunol. Today, 1994, vol. 15, No. 10, pp. 490-495.
Himelstein et al, “Metalloproteinases in Tumor Progression: The Contribution of MMP-9”,Invasion Metastasis, 1994-95, 14, pp. 246-258.
Ho et al, “Treatment of severe lichen planus with cyclosporine”,J. Am. Acad. Dermatol., 1990, vol. 22, No. 1, pp. 64-68.
Gum et al, “Stimulation of 92-kDa Gelatinase B Promoter Activity byrasIs Mitrogen-activated Protein Kinase . . . ”,J. Biol. Chem., 1996, vol. 271, No. 18, pp. 10672-10680.
Litwin et al, Novel Cytokine-independent Induction of Endothelial Adhesion Molecules Regulated by Platelet/Endothelial Cell Adhesion Molecule (CD31),J. Cell Biol., 1997, vol. 139, No. 1, pp. 219-228.
Newman, “Perspective Series: Cell Adhesion in Vascular Biology”,J. Clin. Invest., 1997, vol. 99, No. 1, pp. 3-8.
Hakugawa et al, “The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil . . . ”,J. Dermatol., 1997, vol. 24, pp. 73-79.
Demers et al, “Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA)”,Nucl. Acid Res., 1995, vol. 23, No. 15, pp. 3050-3055.
Shea et al, “Synthesis, Hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates”,Nucl. Acid Res., 1990, vol. 18, No. 13, pp. 3777-3783.
Oberhauser et al, “Effective incorporaiton of 2′O-methyl-oligoribonucleotides into lipsomes and enhanced cell association . . . ”,Nucl. Acid Res., 1992, vol. 20, No. 3, pp. 533-538.
Regezi et al, “vascular adhesion molecules in oral lichen planus”,Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 1996, vol. 81, No. 6, pp. 682-690.
Hegemann et al, “Biochemical Pharmacology of Protein Kinase C and its Relevance for Dermatology”,Pharmacol. of the Skin, 1992, Chapter 22, pp. 357-368.
Bernhard et al, “Direct evidence linking expression of matrix metalloproteinase 9 (92- kDa gelatinase/collagenase) . . . ”,Proc. Natl. Acad. Sci. USA, 1994, vol. 91, pp. 4293-4297.
Dean et al, “Inhibition of protein kinase C-α expression in mice after systemic administration . . . ”Prac. Natl. Acad. Sci. USA, 1994, vol. 91, pp. 11762-11766.
Letsinger et al, “Choleste

Affiliated with

Also associated with

Rating

Oligonucleotide analogues and methods utilizing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotide analogues and methods utilizing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide analogues and methods utilizing the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4228705